Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 6:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 644 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Lacrimal Apparatus Diseases Clear all
Completed No phase listed Observational

The Relationship of Residence Time and Visual Effect of Optive and Systane in Dry Eye Subjects

NCT00553579
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Not listed
Lead sponsor
Southern California College of Optometry at Marshall B. Ketchum University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Fullerton, California
Source: ClinicalTrials.gov public record
Updated May 20, 2008 · Synced Oct 22, 2026, 6:37 PM EDT
Recruiting Phase 2 Interventional

Low-Dose Atropine Eye Drops for Excessive Tearing (Epiphora)

NCT07816224
View directory record Official record
Conditions
Epiphora
Interventions
Atropine sulfate ophthalmic solution 0.005%, Vehicle arm
Drug
Lead sponsor
Rehan Ahmed
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Houston, Texas • Mesquite, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 22, 2026, 6:37 PM EDT
Terminated Phase 2 Interventional Results available

Dexamethasone Irrigation of the Parotid Glands in Primary Sjögren's Syndrome Subjects

NCT01316770
View directory record Official record
Conditions
Sjögren's Syndrome, Xerostomia
Interventions
Dexamethasone Parotid Irrigation, Placebo Parotid Irrigation
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
18 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 2, 2018 · Synced Oct 22, 2026, 6:37 PM EDT
Completed Phase 1Phase 2 Interventional Results available

IVW-1001 Phase 1/2 in Subjects With Dry Eye Disease

NCT06400459
View directory record Official record
Conditions
Dry Eye Disease
Interventions
IVW-1001 Ophthalmic Eyelid Wipe 0.1%, IVW-1001 Ophthalmic Eyelid Wipe 0.2%, IVW-1001 Placebo
Drug
Lead sponsor
IVIEW Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 22, 2026, 6:37 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Intracanalicular Dexamethasone Compared to Loteprednol Etabonate in Patients With Keratoconus

NCT04418999
View directory record Official record
Conditions
Keratoconus, Dry Eye, Allergy
Interventions
dexamethasone ophthalmic insert 0.4 mg, for intracanalicular use, Loteprednol Etabonate 0.38% Ophthalmic Gel/Jelly
Drug
Lead sponsor
Illinois College of Optometry
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 22, 2026, 6:37 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry Eye

NCT01257607
View directory record Official record
Conditions
Dry Eye
Interventions
MIM-D3 Ophthalmic Solution, Placebo Ophthalmic Solution
Drug
Lead sponsor
Mimetogen Pharmaceuticals USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Oct 22, 2026, 6:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Total30 For Contact Lens Dropouts

NCT06967298
View directory record Official record
Conditions
Dry Eye, Contact Lens Complication, Contact Lenses
Interventions
T30 Contact lenses
Device
Lead sponsor
Southern College of Optometry
Other
Eligibility
18 Years to 40 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 22, 2026, 6:37 PM EDT
Completed Not applicable Interventional Results available

Acute Comfort of Lubricant Eye Drops FID 112903

NCT00673855
View directory record Official record
Conditions
Dry Eye
Interventions
Lubricant Eye Drops FID 112903, Optive Lubricant Eye Drops
Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Mansfield, Texas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Oct 22, 2026, 6:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluate the Safety and Efficacy of a New Artificial Tear for Use After LASIK Surgery

NCT00544713
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
Carboxymethylcellulose and Glycerin based artificial tear, Carboxymethylcellulose
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 14, 2011 · Synced Oct 22, 2026, 6:37 PM EDT
Not yet recruiting Phase 4 Interventional

Effect of Acoltremon Ophthalmic Solution 0.003% on Tear Production and Symptoms in Patients With Tear Deficiency and Concurrent Neuropathic Corneal Pain

NCT07849803
View directory record Official record
Conditions
Ocular Pain, Dry Eye
Interventions
acoltremon ophthalmic solution 0.003%
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 22, 2026, 6:37 PM EDT
Recruiting Phase 3 Interventional

Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden

NCT07621809
View directory record Official record
Conditions
Sjögren´s Disease
Interventions
VAY736, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
570 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
20
States / cities
Peoria, Arizona • Clearwater, Florida • Tampa, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 22, 2026, 6:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of Extended Tear Film Break Up Time (TFBUT) With an Ocular Emulsion

NCT01368198
View directory record Official record
Conditions
Dry Eye
Interventions
Systane Balance Lubricating Eye Drops, OPTIVE™
Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Oct 22, 2026, 6:37 PM EDT
Completed Not applicable Interventional Results available

Dry Eye Symptom Relief Assessment With Use of TrueTear in a Controlled Adverse Environment

NCT03097614
View directory record Official record
Conditions
Dry Eye, Dry Eye Syndromes
Interventions
TrueTear
Device
Lead sponsor
Oculeve, Inc.
Industry
Eligibility
22 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 18, 2018 · Synced Oct 22, 2026, 6:37 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Characterization of Diseases With Salivary Gland Involvement

NCT02327884
View directory record Official record
Conditions
Healthy Volunteer, Sjogren's Syndrome, Salivary Gland Disease
Interventions
Not listed
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
4 Years to 100 Years
Enrollment
1,150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2032
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 22, 2026, 6:37 PM EDT
Completed No phase listed Observational

Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity

NCT03941184
View directory record Official record
Conditions
SCAD, Addison Disease, Ankylosing Spondylitis, Antiphospholipid Antibody Syndrome, Celiac Disease, Crohn Disease, Dermatomyositis, Polymyositis, Guillain-Barre Syndrome, Hepatitis, Autoimmune, Graves Disease, Hashimoto Thyroiditis, Multiple Sclerosis, Myasthenia Gravis, Pernicious Anemia, Polymyalgia Rheumatica, Primary Biliary Cirrhosis, Psoriasis, Rheumatoid Arthritis, Systemic Sclerosis, Sjögren Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Type 1 Diabetes Mellitus, Ulcerative Colitis, Uveitis, Vasculitis, Vitiligo, Raynaud
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 110 Years
Enrollment
114 participants
Timeline
1995 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 22, 2026, 6:37 PM EDT
Completed Phase 2 Interventional

A Study of TL-925 as a Treatment for Dry Eye Disease

NCT05745064
View directory record Official record
Conditions
Dry Eye Disease
Interventions
TL-925, Placebo
Drug
Lead sponsor
Telios Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
4
States / cities
Newport Beach, California • Colorado Springs, Colorado • Indianapolis, Indiana + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 22, 2026, 6:37 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease

NCT02813265
View directory record Official record
Conditions
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Interventions
KPI-121 0.25% Ophthalmic Suspension, Vehicle of KPI-121 0.25% Ophthalmic Suspension
Drug
Lead sponsor
Kala Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
918 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
60
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 53 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 22, 2026, 6:37 PM EDT
Completed Phase 4 Interventional

Efficacy and Safety of a New Multi-dose Lubricant Eye Drop Concomitant With Restasis® (Cyclosporine A) for the Treatment of Dry Eye Symptoms

NCT00405457
View directory record Official record
Conditions
Dry Eye
Interventions
Restasis, Optive Tears
Drug
Lead sponsor
Innovative Medical
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 22, 2010 · Synced Oct 22, 2026, 6:37 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Efficacy of OmegaBoost to Increase Omega-3 Levels in Healthy Individuals

NCT05763940
View directory record Official record
Conditions
Dry Eye Syndromes, Age-Related Macular Degeneration, Omega 3 Index
Interventions
OmegaBoost, Nature Made (soft gel), Nature Made (gummy)
Dietary Supplement
Lead sponsor
Western University of Health Sciences
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Pomona, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 22, 2026, 6:37 PM EDT
Completed Phase 2 Interventional Results available

Research Study To See How Well An Eye Drop (SURF-200) Works, What Side Effects There Are, And To Compare It With Vehicle In Subjects With An Episodic Flare-Up of Dry Eye Disease

NCT04734210
View directory record Official record
Conditions
Dry Eye Disease
Interventions
0.02% Betamethasone Sodium Phosphate, 0.04% Betamethasone Sodium Phosphate, Placebo
Drug
Lead sponsor
Surface Ophthalmics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
28
States / cities
Dothan, Alabama • Azusa, California • Mission Hills, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 22, 2026, 6:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study of the TearCare System in Dry Eye Disease

NCT03588624
View directory record Official record
Conditions
Dry Eye
Interventions
TearCare
Device
Lead sponsor
Sight Sciences, Inc.
Industry
Eligibility
22 Years and older
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
3
States / cities
Newport Beach, California • Arlington Heights, Illinois • Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 22, 2026, 6:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Computer Screen Properties Study

NCT05042960
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Brightness
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 22, 2026, 6:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Meibomian Gland Dysfunction Management With ZEST Protocol

NCT03968731
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Dry Eye Syndromes, Ocular Surface Disease
Interventions
Zocular Eyelid System Treatment
Other
Lead sponsor
University of the Incarnate Word
Other
Eligibility
21 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2022 · Synced Oct 22, 2026, 6:37 PM EDT
Completed Phase 1 Interventional

Topical Naloxone to Diagnose Ocular Pain

NCT04454281
View directory record Official record
Conditions
Dry Eye Syndromes, Neuropathic Pain
Interventions
Naloxone Hydrochloride 0.4 MG/ML
Drug
Lead sponsor
Seema Capoor
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 22, 2026, 6:37 PM EDT